Prime Medicine financials
$3.09+7.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $856.0K | $838.0K | $1.2M | $1.1M | $1.5M | $2.2M | $209.0K | $0.00 | $591.0K | $0.00 | $0.00 |
| Gross profit | $1.2M | $856.0K | $838.0K | $1.2M | $1.1M | $1.5M | $2.2M | $209.0K | $0.00 | $591.0K | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | 100.0% | — | — |
| Operating income | -$43.3M | -$50.7M | -$48.6M | -$54.0M | -$53.4M | -$52.4M | -$44.2M | -$54.2M | -$55.7M | -$48.3M | -$68.0M | -$51.5M |
| Net income | -$42.1M | -$49.1M | -$46.1M | -$50.6M | -$52.6M | -$51.9M | -$42.3M | -$52.5M | -$55.3M | -$45.8M | -$65.6M | -$50.7M |
| Net margin | −3649.0% | −5738.6% | −5498.7% | −4129.1% | −4716.7% | −3568.8% | −1936.6% | −25128.2% | — | −7743.0% | — | — |
| Diluted EPS | $-0.24 | $-0.28 | $-0.26 | $-0.32 | $-0.41 | $-0.40 | $-0.32 | $-0.44 | $-0.46 | $-0.44 | $-0.71 | $-0.55 |
| EBITDA | -$41.5M | -$48.8M | -$46.7M | -$52.1M | -$51.5M | -$50.7M | -$42.5M | -$52.7M | -$54.1M | -$47.0M | -$66.8M | -$50.2M |
| Operating cash flow | -$41.0M | -$42.7M | -$37.3M | -$35.0M | -$41.4M | -$48.9M | $16.2M | -$25.9M | -$45.5M | -$67.7M | -$43.9M | -$39.2M |
| Free cash flow | -$41.1M | -$42.9M | -$37.5M | -$35.3M | -$43.0M | -$51.3M | $14.5M | -$27.2M | -$47.4M | -$70.0M | -$45.7M | -$42.1M |
| Diluted shares | 177.2M | 177.1M | 174.5M | 160.5M | 129.2M | 130.9M | 131.0M | 119.8M | 119.2M | 104.5M | 92.5M | 91.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $47.5M | $64.1M | $63.0M | $71.4M | $53.8M | $91.9M |
| Short-term investments | $47.6M | $71.4M | $114.6M | $141.9M | $44.5M | $52.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $249.0M | $294.7M | $342.7M | $385.0M | $279.0M | $328.2M |
| Total liabilities | $209.2M | $218.0M | $221.9M | $223.2M | $218.1M | $221.2M |
| Shareholders' equity | $39.8M | $76.7M | $120.9M | $161.8M | $60.9M | $106.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology